tiprankstipranks

Tiziana Life Sciences CEO to Present at ROTH Conference

Story Highlights
  • Tiziana Life Sciences’ CEO will present at the ROTH Conference in March 2025.
  • The presentation will focus on intranasal foralumab’s promising results in treating multiple sclerosis.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Tiziana Life Sciences CEO to Present at ROTH Conference

Tiziana Life Sciences ( (TLSA) ) just unveiled an update.

On March 17, 2025, Tiziana Life Sciences announced that its CEO, Ivor Elrifi, will present at the 37th Annual ROTH Conference, held from March 16-18, 2025, in Dana Point, California. The presentation will include a fireside chat and 1×1 investor meetings, highlighting the company’s lead candidate, intranasal foralumab, which has shown promising results in treating non-active secondary progressive multiple sclerosis. This event is a significant opportunity for Tiziana to showcase its innovative therapies to a broad audience of investors and industry leaders, potentially enhancing its market positioning and stakeholder engagement.

More about Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. The company is particularly noted for its intranasal foralumab, a fully human anti-CD3 monoclonal antibody, which is currently in clinical development to treat neuroinflammatory and neurodegenerative diseases.

YTD Price Performance: 130.88%

Average Trading Volume: 1,019,402

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $173.7M

See more insights into TLSA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App